2,3-Dihydroxy-6-nitro-7-sulfamoylbenzo(F) quinoxaline (NBQX), an ex-amino-3-hydroxy-5-methyl-4isoxazole propionic acid (AMP A) receptor antagonist, has been reported to provide neuronal protection after global ischemia. The objectives of this study were to eval uate the neuroprotective effects of NBQX initiated after focal cortical ischemia and to validate a method for mea suring functional outcome in this model. Male spontane ously hypertensive rats (SHRs) were exposed to various durations of transient or permanent tandem middle cere bral artery (MCA) occlusion. Studies compared motor performance using balance beam and prehensile-traction tests, calcium-calmodulin (Ca-CaM) binding by immuno histochemistry, and infarct volume between NBQX treated animals [intravenous (i. v.) 5 mg/kg/h x 6 h or intraperitoneal (i.p.) 30 mg/kg q 30 min x 3 begun postis chemia] and controls. All ischemic groups performed less well than sham-operated controls on the motor perfor mance tasks in proportion to the severity of ischemia. No
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The process of evaluating the effectiveness of a neuronal protective agent after an ischemic insult is multifaceted. In addition to measuring the preser vation of neuronal populations by histologic analy sis, the ultimate goal of a neuroprotective agent in significant improvement in motor performance was noted in the NBQX-treated versus the control animals after 1 h or permanent MCAICCA occlusion. Treatment with NBQX (i.v. or i.p. dosing) did not reduce Ca-CaM bind ing after 1 h of occlusion with 1 h of reperfusion or after 2 h of occlusion. Similarly, there was no reduction in infarct size between NBQX-treated and control animals after 24 h of permanent MCAICCA occlusion (74.6 ± 7.1 vs. 80.1 ± 6.0 ml; ns) or after 1 h of occlusion with 23 h of reperfusion (55.1 ± 4.4 vs. 47.4 ± 6.2 ml; ns). We conclude that therapy with NBQX alone has no protec tive effect in this model of ischemia, which may be related in part to its inability to prevent a postischemic increase in intracellular Ca in cortical neurons, and that our method of measuring motor performance is a useful indi cator of functional outcome in this model. Key Words: Calcium-Calmodulin-Focal ischemia-Motor perfor mance-NBQX. acute ischemic injury is the preservation of func tional and behavioral activity. Inasmuch as the mid dle cerebral artery (MCA)/common carotid artery (CCA) tandem occlusion model mirrors focal infarc tion in humans, determination of a reliable method for testing functional motor performance, along with histologic survival, and establishment of the mechanism of action are essential for the preclinical evaluation of a possible neuroprotective agent.
The discovery of the competitive non-N-methyl D-aspartate (NMDA) glutamate receptor antagonist quinoxalinediones provides the opportunity to ex plore the neuroprotective benefit of non-NMDA re ceptor blockade after ischemic injury. The potent and selective u-amino-3-hydroxy-5-methyl-4isoxazole propionic acid (AMPA) antagonist, 2,3dihydroxy-6-nitro-7 -sulfamoyl-benzo(F)quinox aline (NBQX), has been shown to be effective in reducing neuronal loss in the CAl region of the hip pocampus after brief durations of global ischemia (Buchan et aI., 1992; Nellgard et aI., 1992; Pulsinelli and Cho, 1992) , as well as in transient focal neo cortical ischemia (Buchan et aI., 1991) . These agents are of particular interest since they have no significant activity at the glutamate, glycine, or phencyclidine binding sites of the NMDA receptor (Sheardown et aI., 1990) . Because of the behavioral side effects that may arise from the use of agents that antagonize the NMDA-receptor complex (Wil letts et at., 1990; Cosgrove and Newell, 1991) , the quinoxalinediones represent a possible alternative for ischemic neuronal protection.
In this study, using three separate methods, we endeavored to assess the protective role of NBQX begun after a focal cortical ischemic insult. First, we evaluated its ability to reduce the infarct vol ume. Second, we determined whether NBQX atten uated the increase in ischemia-induced calcium (Ca) influx by measuring neuronal Ca-calmodulin (CaM) binding using an immunohistochemical assay for free calmodulin. Though early reports concluded that non-NMDA receptor channels are imperme able to Ca2+ (Mayer et aI., 1987; Ascher and No vak, 1988) , more recent studies indicate that some glutamate receptor subgroups are permeable to di valent cations (Murphy and Miller, 1989; Hollmann et aI., 1991) . Finally, we determined the ability of NBQX to preserve motor performance. Behavioral motor performance paradigms have been used to analyze both global (Volpe et aI., 1984; Combs and D'Alecy, 1987) and focal animal stroke models (Be derson et aI., 1986; Young et aI., 1986; Germano et aI., 1987; Yamamoto et aI., 1988; Markgraf et aI., 1992) . In the present study, a method for measuring motor performance in this model of focal pure cor tical ischemic injury has been developed and em ployed for examining functional recovery.
METHODS
Male spontaneously hypertensive rats (SHRs) weighing 250-300 g were fasted overnight with free access to water and anesthetized with chloral hydrate intraperitoneally (Lp.) prior to surgery. The femoral artery was cannulated with a polyethylene catheter for blood pressure monitor ing and serial blood gas sampling. A microprobe was used to monitor skull temperature, maintained with a heating lamp and warming blanket at 37 ± 0.5°C, as was the rectal temperature. The right common carotid artery was iso lated through a midline ventral cervical incision and tagged with 3.0 silk. An incision was made perpendicular to a line between the external auditory canal and the lat eral canthus of the right eye through the temporalis mus cle, which was retracted with 4.0 silk. Under direct visu alization with a Zeiss surgical microscope, the right MCA was exposed through a 1 x 3-mm burr hole drilled 2-3 mm rostral to the fusion of the zygomatic arch with the squamosal bone. A continuous 0.9% saline drip was maintained over the drilling site to prevent thermal injury to the underlying brain tissue. Once the MCA was visible through the transparent bone layer, a jeweler's forceps was used to remove the remaining bone. A 23-gauge hy podermic needle was used to pierce and open the dura along the entire length of the burr hole.
The method used for producing reversible ischemia was a modification of the procedure described previously (Brint et al., 1988; Kaplan et al., 1991) . A 10-0, BV130-5 Ethicon Neurosurgical suture was placed under the MCA rostral to the rhinal fissure, proximal to the major bifur cation of the MCA, but distal to the lenticulostriate arter ies. The MCA was lifted -1 mm and the suture was ro tated clockwise so that one end pointed toward the frontal bone, forming a right angle to the long axis of the burr hold. Verification of the absence of blood flow was made visually with the surgical microscope. Immediately after MCA occlusion, the right common carotid artery was oc cluded using two atraumatic Heifetz aneurysm clips. Reperfusion was achieved by turning the suture counter clockwise and removing it. Aneurysm clips were re moved and flow in both the CCA and the MCA was con firmed visually with the operating microscope. In rats exposed to 24 h of focal ischemia, permanent ligation of the right CCA and MCA was performed. Again, absence of blood flow was verified visually. This technique pro duces a nearly exclusive cortical infarction, sparing the deep white matter and basal ganglia.
Rats were treated with either intravenous (L v.) N a + salt NBQX at 5 mg/kg/h in 3 rnl of sterile water initiated immediately after MCA occlusion and infused over 6 h, versus i.v. saline controls, or NBQX, 30 mg/kg/ Lp. every 30 min x 3, begun 30 min after MCA occlusion, versus i.p. saline controls. We were unable to use a higher dose of intravenous NBQX, i.e., 15 mg/kg/h in 3 ml sterile water, because of precipitation of the drug in the vein at the i. v. site, with a concomitant mortality of -50%.
To measure alterations in intracellular Ca concentra tions, we used an immunohistochemical assay for free CaM described previously (Picone et aI., 1989) . In previ ous studies in our lab (DeGraba et al., 1993) , we found that a significant increase in Ca concentration as mea sured by Ca-CaM binding occurred by 1 h of focal isch emia and was maximal by 4 h, with close correlation with histologic damage. We wanted to use durations of isch emia with demonstrable, but submaximal, Ca2+ influx to measure the effect of NBQX. Therefore, animals to be studied for CaM immunostaining were exposed to either 1 h of ischemia with 1 h of reperfusion or 2 h of ischemia.
After being anesthetized with ethyl ether (purified grade), rats were perfused through the heart with 4% paraformaldehyde, then killed, and brain slice prepara tions (40-f.Lm thickness) were incubated in sheep-induced CaM antibody, which binds specifically to free CaM (i.e., CaM not bound to Ca2 + and target protein) (Picone et al., 1989) . The sections were incubated with rabbit anti-sheep peroxidase-conjugated secondary antibody, which binds and stains only CaM-antibody complex (Picone et al., 1989) . Thus, only normal cells with free CaM will stain, and ischemic cells with a Ca2 + -activated CaM-target pro tein complex do not stain (Picone et al., 1989) . Prior stud ies in our lab have shown that there are no significant changes in the concentrations of CaM or its target pro teins in postischemic rat brains. Therefore, changes in CaM staining are believed to be secondary to increased intracellular Ca2+ and subsequent Ca-CaM binding. Sets of normal and postischemic brains were processed simul taneously to ensure comparable staining. Staining in the ischemic region of each animal exposed to focal ischemia was graded on a scale of 0 to 15 (0 = normal, 15 = largest area of severe loss of CaM staining) (DeGraba et aI., 1993) .
For measurement of infarct volume, animals were ex posed to 1 h of occlusion with 23 h of reperfusion or to 24 h of permanent occlusion. As above, the animals were randomized to two dosing regimens. The low-dose group received NBQX sodium salt, 5 mg/kg/h i.v. x 6 h, initi ated immediately after the onset of ischemia, versus a saline control. The other treatment group received NBQX sodium salt, 30 mg/kg i.p. in 1 ml sterile water, at 30, 60, and 90 min after MCA occlusion, versus a saline control. At 24 h, under ether anesthesia, all the rats were perfused with phosphate-buffered 10% formalin, and sac rificed. The brains were removed and examined to verify the presence or absence of MCA occlusion. After embed ding the whole brain in paraffin, 5-j-Lm slices were sec tioned at 0.5-mm intervals, stained with luxol fast bluel hematoxylin and eosin, and digitized on an Amiga com puter to calculate the infarct volume.
CaM stain grading and histologic grading were carried out by a blinded investigator.
Motor performance was measured using a combined grading scale consisting of a modification of the balance beam test and the prehensile-traction test (Combs and D'Alecy, 1987) after either 1 h or permanent MCAICCA occlusion and in sham-operated controls.
Prior to surgery, rats underwent motor performance training sessions (described below) for 2 consecutive days. The animals were scored on the morning of surgery (baseline score) and then on the mornings of postopera tive days 1, 2, 3, 4, 5, and 7. Two trials of each motor tasks were observed per day, with 5 min of rest between trials to prevent fatigue. The best score of the two trials was recorded. NBQX in the two drug regimens (5 mg/kg/h x 6 h i. v. started immediately after the onset of ischemia or 30 mg/kg i.p. 30, 60, and 90 min after ischemic onset) with the appropriate controls was administered.
In the balance beam test, rats were placed at the center of an unfinished wooden beam (2.5-cm diameter), sup ported 40 cm above a foam pad (1 0 cm thick). Time to falling off the beam was recorded to a maximum of 30 s (Table 1) . A zero was scored if the rat was unable to maintain a grip or balance on the beam. The rat received a 1 if it remained balanced up to 10 s, a 2 for 11-20 s, and a 3 for 21 -30 s. The maximal possible score for this task was 3.
In the prehensile-traction test, the rat's forepaws were .5 9 c: placed on a nylon rope positioned horizontally 70 cm above a foam pad (1 0 cm thick). The ability to maintain a grip on the rope for up to 15 s was recorded in the pre hensile portion of the test, indicating predominantly mo tor strength. The traction portion of the test evaluates the animal's ability to bring one hind limb up to the rope (Table 1) . The rat received a 0 if the time to falling was 0-5 s, a 1 if it maintained a grip for 6-10 s, and a 2 if it maintained a grip for 11-15 s. An additional point was scored if the rat was able to bring one hind leg to the rope within the 15-s period, for a possible maximal score of 3 points.
The combined total of the best score for each test was recorded by an investigator blinded to the durations of ischemia. Motor performance testing was done at the same time each day to avoid diurnal variation in activity, and treatment and control groups were tested simulta neously to minimize potential animal care variation, which could affect performance.
RESULTS
The monitoring of physiologic variables, includ ing mean arterial pressure, arterial blood gases, and head temperature, revealed no significant differ ences between the NBQX-treated and the control animals. Though blood pressure was noted to de crease 20-25% during the period of ischemia, the decline was equal in both the treatment and the con trol groups. Mortality was 6% in controls and 4 and 6% with i.v. and i.p. NBQX therapy, respectively.
After 1 h of MCAICCA occlusion, followed by 1 h of reperfusion, and 2 h of occlusion, no difference in Ca-CaM binding was found between the control and the i.p. NBQX-treated groups (mean ± SD = 8.66 ± 1.53 vs. 11.62 ± 2.33 and 11.11 ± 1.54 vs. 12.13 ± 2.10, respectively) (Fig. 1) . The i. v. dosing demonstrated similar results (data not shown).
Treatment with either i.v. or i.p. NBQX caused no significant reduction in infarct size compared to controls (55.1 ± 12.4 vs. 47.2 ± 18.0 vs. 47.4 ± 20.5 mm3, respectively) after 1 h of occlusion with 23 h of reperfusion or between i.v. NBQX-treated rats and controls after 24 h of occlusion (74.5 ± 22.5 vs. 80.1 ± 17.0 mm3) (Fig. 2) .
Finally, treatment with i.p. or i.v. NBQX did not significantly improve motor performance after 1 h of transient ischemia (Fig. 3A) or permanent MCAI CCA occlusion (Fig. 3B ) compared to control ani mals (i.v. data not shown). In the permanently oc cluded group, ischemic control animals and those treated with NBQX had persistent significantly lower motor performance scores on days 2 through 7 compared to sham-operated rats. The same trend was seen in the transient MCAICCA occlusion groups, though statistical significance was not reached until days 5 and 7.
Though not directly measured or quantitated, ataxic behavior and unsteadiness were noted in 83% of the i.p.-treated animals. This behavior, if seen, characteristically was noted by postoperative day 3. Since there appeared to be no correlation with mo tor performance (which specifically tested strength), it was felt not to be attributed to weak ness. Histological examination of the cerebellum and basal ganglia at the end of the week of motor performance testing failed to reveal any consistent pattern of neuronal injury.
DISCUSSION
The effect of AMP A antagonists on ionic flux provide a strong theoretical basis to support the hy- There was no difference in infarct volume between controls and NBQX-treated animals. pothesis that they would have a neuroprotective ef fect after an acute ischemic insult. However, unlike previous reports of a reduction of infarct size in rats treated with NBQX after focal ischemia (Buchan et aI., 1991) as well as a preliminary report (Pulsinelli and Cho, 1992) demonstrating neuronal protection when NBQX was administered (30 mg/kg i.p. x 3) up to 8 h after 10 min of global ischemia, we were unable to demonstrate protection of cortical neuron morphology, Ca2+ homeostasis, or motor perfor mance in our model of focal ischemia.
NBQX was not effective in reducing infarct size after either a maximal or a submaximal ischemic insult. There are several possibilities for this lack of protection. In the paradigm of submaximal isch emia, neuronal injury most likely is the result of excitotoxicity mediated by both NMDA and non NMDA receptors. Consequently, monotherapy with an AMP A receptor antagonist may be insuffi cient in protecting the neuron. It has been demon strated that after severe ischemic injury, a decrease in extracellular pH inhibits NMDA receptor mediated Ca influx (Tang et aI., 1990) . Thus, exci totoxicity mediated by the non-NMDA receptor might play a more dominant role in the severe isch emic injury caused by global ischemia, and this may explain the benefit reported even after a delay of 8 h before the initiation of NBQX therapy (Pulsinelli and Cho, 1992) . Even with permanent MCAICCA tandem occlusion, regional cerebral blood flow in this model has been reported to persist at � 19 to 29 mllOO g-l min-1 (Brint et aI., 1988) , thus allowing glutamate activation of multiple receptor types to play a role in neuronal injury. This may explain why NBQX alone was not effective in our study even after permanent occlusion.
To understand better the mechanism of action of NBQX, we used an immunohistochemical assay of free CaM to measure increased intracellular Ca ac tivity after ischemia (Picone et aI., 1989; DeGraba et aI., 1993) . In this study, extensive Ca-CaM bind ing, which we have shown correlates with histolog ical damage (Picone et aI., 1989; DeGraba et aI., 1992 DeGraba et aI., , 1993 , was not attenuated by NBQX therapy. Therefore, it would appear that even if blockade of the AMP A receptor does marginally reduce Ca2 + influx, either by antagonizing a non-NMDA recep tor subtype that mediates Ca2+ flux or by decreas ing intracellular voltage changes, thus attentuating the opening of voltage-dependent (L) Ca2+ chan nels (Choi, 1988) , activation of other mechanisms must be sufficient to increase the intracellular Ca2 + concentration and initiate Ca2+ -mediated neuronal injury.
Other reasons for the lack of neuronal protection Days Post Op 5 in our study include variability in the tissue distri bution of NBQX. After sacrificing our rats receiv ing i.p. NBQX, examination of the abdominal cav ity revealed crystallization of the drug on the peri toneal wall. In addition, with both i.v. and i.p. administration of the drug, there was marked yel low discoloration of the rat's tail and coat as well as the visceral organs and urine. We also observed that the sodium salt of NBQX at higher concentra tions precipitated at the venous infusion site. Such peripheral tissue and organ deposition would lead to interanimal variability in blood levels. However, the doses, vehicle, and method of administration used in this study were the same as reported in previously published positive experiments (Buchan et al., 1991; Pulsinelli and Cho, 1992) . Furthermore, i.p. administration of the same doses of the sodium salt of NBQX to male Wistar rats resulted in pre dictable peak plasma concentrations of 5-10 Ilg/ml (data on file, Novo Nordisk Corp. central nervous system penetration. Therefore, while unfavorable pharmacokinetics may be an im portant contributor to our negative results, they are not the entire explanation. Another possible explanation for the lack of ben efit from NBQX is the small "penumbra" seen in this model, which is believed to be the zone of isch emic insult in which neuronal protection is most likely to occur with this type of therapy. However, Kaplan et al. (1991) demonstrated little to no in farcted tissue at ischemic periods of < 1 h and in farct volumes of -to, 100, and 150 mm3 (maximum) after 1, 2, and 3 h of ischemia, respectively, in this model. Since in the present study ischemic dura tions were 1, 2, and 24 h, with drug therapy initiated within 30 min of the onset of ischemia, there is a reasonable likelihood that the drug was being given during a submaximal insult. If the drug has neuro protective effects, it is not unreasonable to expect it to show some benefit in this setting. Furthermore, we have found a reduction of infarct volume with a competitive NMDA receptor antagonist and with hypothermia in this model (unpublished data).
We have found that neuroprotective therapy may improve working memory as well as electrophysio logic parameters without detectable histologic pro tection (Grotta et aI., 1988 (Grotta et aI., , 1990 . Behavioral as sessment is still poorly defined in this model of focal ischemia. Since the ultimate goal in developing a therapy for acute stroke in humans is to improve overall functional outcome, an analysis of neuro logic function must eventually be included in the preclinical evaluation of a therapy's effectiveness. We used a modification of the balance beam and prehensile-traction tests to measure functional out come. Though no improvement in motor perfor mance was seen with the administration of NBQX versus controls, our method appears to be reliable for future preclinical studies in the assessment of neuroprotective therapy utilizing a relatively small number of rats (six per group). Analysis of the scores demonstrated a persistent significant motor performance deficit in the permanent MCAICCA occlusion rats on postoperative days 2 through 7 compared to sham-operated animals. A significant though less dramatic decrease in motor perfor mance was also seen in the I-h occlusion rats versus shams on days 5 and 7. Though performance scores were noted to be somewhat higher in the I-h versus permanent occlusion rats, a larger number of ani mals per group (18-23) would be required to guar antee recognition of a 25% difference in motor per formance between these two degrees of ischemia with a certainty of 0.90.
Further analysis of the individual tasks revealed that the balance beam test was less sensitive for detecting mild deficits occurring after 1 h of tran sient occlusion. In addition, it was noted that the rats were less likely to perform the motor behavior traction task with successive daily trials, despite their ability to maintain a grip on the rope for greater than 15 s. This "fatigue" in performance of the traction task was seen not only in the ischemic and control groups but also in the sham animals and may represent a loss of motivation to complete the task. Therefore, unless some incentive can be added to ensure that the task is a function of capa bility rather than interest, the traction component may not be reliable for sequential testing.
In an effort to quantify better the neurologic def icit after a MCA infarction, Bederson et al. (1986) described circling behavior after severe proximal MCA occlusion. In our model of exclusive cortical infarction and no subcortical involvement, none of the 12 rats with permanent MCAICCA occlusion exhibited circling behavior. Therefore, even with a maximal-MCA distribution cortical infarction, cir cling behavior appears to require additional in volvement of the basal ganglia and is not reliable as a measure of functional injury in this model. This highlights the fact that similar models of ischemia may aff ect different brain regions, resulting in ab errations of different behaviors. Our findings accent the need for careful standardization of neurologic functional testing for each ischemia model.
In conclusion, NBQX as a single agent showed no significant protective effect on histologic neuro nal injury or motor performance in this model of focal ischemia, possibly related to its inability to prevent Ca2+ influx. However, uncertainty about drug absorption and central nervous system bio availability preclude a definite conclusion about drug activity. An assessment of motor performance is a valid and useful method for measuring outcome in this model.
